Please assess the completion status of the following clinical trial:

Trial Title: Oxaliplatin, Docetaxel, and Radiation Therapy in Treating Patients With Unresectable Stage II/III or Recurrent NSCLC

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of non-small cell lung cancer (NSCLC) meeting 1 of the following criteria:~  * Medically inoperable or unresectable stage II, IIIA, or IIIB disease~ * Post-resection intrathoracic tumor recurrence~* Measurable disease by computed tomography(CT) scan~* No evidence of small cell histology~* No significant pleural effusion on chest x-ray or malignant pleural effusion on cytology~* No metastatic disease~* Eastern Cooperative Oncology Group (ECOG) (Zubrod) performance status 0-1~* Absolute granulocyte count ≥ 2,000/mm³~* Platelet count ≥ 100,000/mm³~* Hemoglobin ≥ 8.0 g/dL~* Bilirubin ≤ 1.5 mg/dL~* Serum glutamic oxaloacetic transaminase (SGOT) ≤ 1.5 times upper limit of normal (unless abnormality is caused by documented benign disease)~* Creatinine ≤ 1.5 mg/dL~* Weight loss ≤ 10% within the past 3 months~* Forced expiratory volume (FEV) 1 ≥ 1,000 cc~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 3 months after completion of study treatment~Exclusion Criteria:~* Synchronous (except for nonmelanomatous skin cancer) or prior invasive malignancy, unless disease free for \> 3 years~* Myocardial infarction within the past 6 months~* Symptomatic heart disease, including any of the following:~  * Angina~ * Congestive heart failure~ * Uncontrolled arrhythmia~* Active infection or fever ≥ 38.5°C within the past 3 days~* Known hypersensitivity to any of the components of oxaliplatin or docetaxel~* Prior thoracic or neck radiotherapy~* Prior docetaxel or oxaliplatin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemoradiation Treated Patients (Type: EXPERIMENTAL): Patients receiving Docetaxel, Oxaliplatin and radiotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).